Taconic Insights

Biopharmaceutical Trends and R&D

Taconic Biosciences has remained one of the world's leading providers of research models and services for over 60 years through our commitment to anticipating clients’ needs and industry trends. One of the key trends of the past ten years involves our clients’ need to strategically outsource functional areas of their R&D programs. When companies, academic institutions, government agencies and others outsource certain R&D functions they begin to rely on their collaborators, such as Taconic, to keep them apprised of emerging science and technologies in our specific areas of expertise.
In this spirit of collaboration, we present "Taconic Insights", a new section of our website dedicated to educating the industry on key scientific and technological trends impacting biopharmaceutical R&D. Here you will find the latest insights Taconic can provide in the form of articles, white papers, videos, webinars, presentations, and other media.

rasH2 Helps Improve Drug Testing

GEN Exclusives has published an article by Amar Thyagarajan, Ph.D., Senior Product Manager at Taconic Biosciences, titled New Guidelines Involve the Testing Done on Animal Models. In his article, Dr. Thyagarajan helps us understand the nature of proposed changes to carcinogenicity safety testing to significantly reduce the amount of time and money it takes to achieve drug approval. A two-year rodent bio-assay to ascertain carcinogenicity has been...

Read More

PDX host selection - avoiding pitfalls with careful planning

Use of patient-derived tumor xenografts (PDX) has increased greatly over the last few years as the utility of these models has been demonstrated. Although early PDX models were developed in standard nude or scid strains, development of such models has increasingly moved to more immunodeficient strains such as NOD scid, NOG or NSG. More immunodeficient strains provide better take rates and faster growth compared to standard nude...

Read More

Additional Mouse Models Added To The Knockout Repository

Taconic Biosciences has recently added an additional 19 mouse models to the Knockout Repository (KOR). The KOR's more than 4,100 lines provide academic and commercial researchers worldwide with unparalleled access to fully licensed knockout mouse models. This repository offers the scientific community immediate access to expertly designed, highly valuable research tools that rapidly accelerate translational research and the drug discovery and development processes. Mutations are focused on...

Read More

You say microbiota, I say microbiome: The 8 word guide to the microbiota

In a recently published article, The vocabulary of microbiome research: a proposal, authors Marchesi and Ravel propose how scientists should use words associated with microbiome, or rather microbiota, research. This editorial published in Microbiome (2015, 3:31), not only proposes how words like Metataxonomics, Metabonomics and Microbiome should be used, it also provides references and technical justification for proper word usage. In a field growing as rapidly as...

Read More

Immune System Engrafted Models FAQ

Immune system engrafted mouse models are becoming more widely used in immuno-oncology research. As their universe of applications grows, questions invariably arise. Our immune system engraftment experts collected answers to a few of these commonly asked questions. huNOG mice are NOG mice engrafted with human CD34+ hematopoietic stem cells (HSCs). They display stable engraftment of multiple cell lineages by 12-16 weeks post-injection. Human lymphocytes are present in...

Read More

Obstacles to efficacy testing of biologic therapies in mice - anti-drug antibody development

Biologic drugs such as monoclonal antibodies or RNA therapies can trigger immune reactions (immunogenicity) upon treatment. Such immune reactions can result in toxicity. Aside from potential safety problems, the immune reaction can also reduce the efficacy of the biologic drug. Production of neutralizing anti-drug antibodies (ADA) in small animal models used for efficacy testing can result in decreased circulating levels of the drug and reduced efficacy. This...

Read More

Meeting report: Tumor Models Boston 2015

The Tumor Models Boston 2015 meeting brought together researchers from North America, Europe and Asia to discuss the application of models to cancer research. The small meeting provided excellent networking and discussion opportunities. Perhaps the most interesting aspect of the meeting was the clear evolution, over just a short time, in the approaches used to study immunotherapies. In contrast to the 2014 meeting, many speakers presented results...

Read More

Mouse model helps accelerate development of new Alzheimer's therapies

The majority of the drugs approved by the FDA for treatment of cognitive symptoms in Alzheimer's disease (AD) patients are cholinesterase inhibitors and include drugs such as donepezil, galantamine, and rivastagimine. However, the tolerated doses of cholinesterase inhibitors, such as donepezil, produce only partial improvement in memory and can have severe GI side effects. Since these medications have to be taken for prolonged durations, the limited efficacy...

Read More

Using CRISPR to change "A" to "T" and "C" to "G"

CRISPR. The use of this acronym has become ubiquitous in the life sciences. For those who don't know, CRISPR stands for Clustered Regularly Interspersed Palindromic Repeats. We hear people talking about it in the context of gene editing of cell lines and animal models. There are now scientific conferences devoted to CRISPR technology, CRISPR in the clinic and CRISPR engineering of animal models. While the intellectual property...

Read More

Unraveling Rare Disease: Taconic's Integrated Solution Supports Vici Syndrome Research

Rare diseases often have a genetic component, so the ability to model a genetic modification and study it in vivo is vital to understanding the disease's mechanisms and identifying therapies. As a leader in the custom development of genetically modified models, Taconic Biosciences is committed to applying our unique capabilities to advance rare disease research. We recently demonstrated that commitment by awarding a $50,000 package of integrated...

Read More